Your session is about to expire
← Back to Search
PVX-2 Vaccine for Atypical Squamous Cells (PVX-2 Trial)
PVX-2 Trial Summary
This trial is testing a new immunization regimen for HPV which consists of two shots of a DNA vaccine and one shot of a TA-CIN vaccine. The goal is to see if this regimen is safe and effective at clearing HPV 16 by Month 6.
PVX-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PVX-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had cancer in the last 5 years.You have a medical condition where your immune system attacks your own body (like rheumatoid arthritis or multiple sclerosis).
- Group 1: Placebo
- Group 2: PVX-2
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people with the required medical condition able to participate in this trial right now?
"That is accurate. The clinical trial in question, which was originally posted on May 22nd, 2019, is still seeking participants. 7 different locations are involved in the recruitment process with a goal of 134 patients total."
Do many hospitals in America offer this type of treatment?
"Right now, there are 7 different sites where this trial is enrolling patients They can be found in Irving, Newark and Austin as well other locations. If you're interested in enrolling, try to choose the site that is closest to your residence to cut down on travel time."
Has the PVX-2 antiviral medication been cleared by the FDA?
"There is limited data on the safety of PVX-2, as this is only a Phase 2 trial. This means that while there are no reports supporting efficacy, there are some positive indicators for safety."
How many study participants are there in total?
"134 patients that meet the clinical trial's inclusion criteria are required in order for the study to have enough statistical power. The sponsor, Parexel, will be running the trial from different sites including MacArthur Medical Center in Irving, New jersey and University Hospital, Rutgers New Jersey Medical School in Newark, Florida."
For which patients is this research project seeking new participants?
"134 patients with squamous intraepithelial lesions of the cervix, aged 25 to 70, are being enrolled in this clinical trial. Most notably, applicants should meet the following criteria: female subjects who are age 25-70 years old and have confirmation of ASC-US, ASC-H, or LSIL by liquid-based cytology; HIV uninfected; Patients whose cytologic specimen is HPV16+ by Aptima HPV 16 18/45 Genotype Assay; Body Mass Index ≤ 32 kg/m2; Hepatitis b surface antigen negative; Anti-hepatitis c virus antibody (anti-HC"
Does this research study have an age limit?
"According to the eligibility requirements set out by the research team, patients must be aged between 25 and 70 to take part in this trial. There is 1 other study available for individuals under 18 years old and 17 studies designed for seniors above the age of 65."
Share this study with friends
Copy Link
Messenger